The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)

Key Facts

Status: Open

Posted date: June 17, 2025

Opportunity ID: 359015

Opportunity number: NOT-DK-26-313

Opportunity category: Discretionary

Agency name: National Institutes of Health

Agency code: HHS-NIH11

Award floor: $0

Award ceiling: $0

Cost sharing required: No

Funding Instrument Types
  • Cooperative Agreement
Category of Funding Activity
  • Health
Eligible Applicants
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities/Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Tools
Categories (use these for quoted searches)
  • agency_code:hhs_nih11
  • category_of_funding_activity:health
  • cost_sharing_or_matching_requirement:false
  • eligible_applicants:county_governments
  • eligible_applicants:for_profit_organizations_other_than_small_businesses
  • eligible_applicants:independent_school_districts
  • eligible_applicants:native_american_tribal_governments_federally_recognized
  • eligible_applicants:native_american_tribal_organizations_other_than_federally_recognized_tribal_governments
  • eligible_applicants:nonprofits_having_a_501_c_3_status_with_the_irs_other_than_institutions_of_higher_education
  • eligible_applicants:private_institutions_of_higher_education
  • eligible_applicants:public_and_state_controlled_institutions_of_higher_education
  • eligible_applicants:public_housing_authoritiesindian_housing_authorities
  • eligible_applicants:small_businesses
  • eligible_applicants:special_district_governments
  • eligible_applicants:state_governments
  • funding_instrument_type:cooperative_agreement
  • opportunity_category:discretionary
  • status:open
Description

The Accelerating Medicines Partnership (AMP), is a pre-competitive collaboration among government, academia, and industry to improve the ongoing efforts to develop new therapies for complex, heterogeneous diseases (http://www.nih.gov/science/amp/). The overarching goal of AMP CMD is to use human genetics as a powerful approach to obtain human-data derived disease understanding and biomarker/therapeutic opportunities. This is being accomplished through systematic aggregation of existing genotype-phenotype data for CMD, related traits, and its complications as well as the generation of a large amount of new omic data. The goal of the NIDDK-funded component of the consortium is to aid in advancing the understanding of the mechanisms responsible for T2D development through the integration of large-scale genetic data that will contribute to further deconstruction of the pathophysiology of T2D, and potentially of its major complications, including macrovascular and microvascular disease. The purpose of this is to request is for renewal of the AMP CMD UM1 program for another 5 years for the portal to aggregate and collate data on T2D/CMD genes and their functional variants so that it can be queried by the scientific community.

The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
The Accelerating Medicines Partnership (AMP), is a pre-competitive collaboration among government, academia, and industry to improve the ongoing efforts to develop new therapies for complex, heterogeneous diseases (http://www.nih.gov/science/amp/). The overarching goal of AMP CMD is to use human genetics as a powerful approach to obtain human-data derived disease understanding and biomarker/therapeutic opportunities. This is being accomplished through systematic aggregation of existing genotype-phenotype data for CMD, related traits, and its complications as well as the generation of a large amount of new omic data. The goal of the NIDDK-funded component of the consortium is to aid in advancing the understanding of the mechanisms responsible for T2D development through the integration of large-scale genetic data that will contribute to further deconstruction of the pathophysiology of T2D, and potentially of its major complications, including macrovascular and microvascular disease. The purpose of this is to request is for renewal of the AMP CMD UM1 program for another 5 years for the portal to aggregate and collate data on T2D/CMD genes and their functional variants so that it can be queried by the scientific community.
The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
Open
National Institutes of Health
Health
Cooperative Agreement
State governments
County governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For-profit organizations other than small businesses
Small businesses
2025-06-17